Growth Metrics

Purple Biotech (PPBT) Short-Term Debt repayments (2019 - 2025)

Purple Biotech has reported Short-Term Debt repayments over the past 4 years, most recently at $83000.0 for Q4 2022.

  • Quarterly Short-Term Debt repayments rose 302.44% to $83000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$41000.0 through Dec 2022, up 73.2% year-over-year, with the annual reading at -$217000.0 for FY2025, 18.58% down from the prior year.
  • Short-Term Debt repayments was $83000.0 for Q4 2022 at Purple Biotech, up from -$41000.0 in the prior quarter.
  • Over five years, Short-Term Debt repayments peaked at $83000.0 in Q4 2022 and troughed at -$108000.0 in Q4 2020.
  • The 4-year median for Short-Term Debt repayments is -$41000.0 (2021), against an average of -$38400.0.
  • Year-over-year, Short-Term Debt repayments crashed 31.71% in 2020 and then surged 302.44% in 2022.
  • A 4-year view of Short-Term Debt repayments shows it stood at -$82000.0 in 2019, then plummeted by 31.71% to -$108000.0 in 2020, then skyrocketed by 62.04% to -$41000.0 in 2021, then surged by 302.44% to $83000.0 in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Short-Term Debt repayments are $83000.0 (Q4 2022), -$41000.0 (Q3 2022), and -$41000.0 (Q2 2022).